The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma
- 1School of Health Medicine, Nantong Institute of Technology
- 2Department of Gynecology and Obstetrics, Affiliated Hospital of Nantong University, Medical School of Nantong University
Abstract
Esophageal squamous cell carcinoma (ESCC) is associated with a poor prognosis, and the efficacy of conventional therapies (chemotherapy, radiotherapy, and surgery) remains limited. The advent of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has substantially altered the treatment paradigm for ESCC. The combination of these immune checkpoint inhibitors (ICIs) with conventional treatments demonstrates significant synergistic potential. Standard oncological regimens often center on chemotherapy, radiotherapy, surgery, or various combinations thereof. This synergy stems from complementary mechanisms: conventional therapies can induce immunogenic cell death, release tumor antigens, and remodel the immunosuppressive tumor microenvironment, thereby laying the groundwork for immunotherapy. In turn, PD-1/PD-L1 inhibitors work by releasing the “brakes” on T cells, activating and enhancing the host anti-tumor immune response. This facilitates the elimination of residual cancer cells and establishes long-term immune surveillance. In conclusion, the combination of PD-1/PD-L1 inhibitors with conventional therapy achieves a greater-than-additive (“1 + 1>2”) effect and has evolved into a standard first-line treatment strategy for advanced/metastatic ESCC, substantially improving patient outcomes. Future research will focus on optimizing combination protocols, overcoming resistance, and precisely identifying patient populations most likely to benefit.
Related
- Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study
- Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care
- The efficacy and safety of combining different commercial Chinese polyherbal preparations with conventional Western drugs in the treatment of diabetic osteoporosis: a network meta-analysis
- Combining interstrand crosslinking agents with histone deacetylase inhibitors against high grade IDH mutant gliomas
- Immune-related adverse events are associated with favorable clinical outcomes in esophageal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
BibTeX
@article{li2026synergistic,
title = {{The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma}},
author = {Ruyan Li and Zihao Heng and Xi Cheng},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1894567},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1894567/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma
AU - Ruyan Li
AU - Zihao Heng
AU - Xi Cheng
PY - 2026
DA - 2026/10/16
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1894567
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1894567/full
AB - Esophageal squamous cell carcinoma (ESCC) is associated with a poor prognosis, and the efficacy of conventional therapies (chemotherapy, radiotherapy, and surgery) remains limited. The advent of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has substantially altered the treatment paradigm for ESCC. The combination of these immune checkpoint inhibitors (ICIs) with conventional treatments demonstrates significant synergistic potential. Standard oncological regimens often center on chemotherapy, radiotherapy, surgery, or various combinations thereof. This synergy stems from complementary mechanisms: conventional therapies can induce immunogenic cell death, release tumor antigens, and remodel the immunosuppressive tumor microenvironment, thereby laying the groundwork for immunotherapy. In turn, PD-1/PD-L1 inhibitors work by releasing the “brakes” on T cells, activating and enhancing the host anti-tumor immune response. This facilitates the elimination of residual cancer cells and establishes long-term immune surveillance. In conclusion, the combination of PD-1/PD-L1 inhibitors with conventional therapy achieves a greater-than-additive (“1 + 1>2”) effect and has evolved into a standard first-line treatment strategy for advanced/metastatic ESCC, substantially improving patient outcomes. Future research will focus on optimizing combination protocols, overcoming resistance, and precisely identifying patient populations most likely to benefit.
SN - 1663-9812
ER -